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1. Introduction {#jia225215-sec-0005}
===============

UNAIDS estimates that there were 1.0 million female and 770,000 male adolescents living with HIV in 2017 (aidsinfo.unaids.org). The adolescent age group (10 to 19 years) represents a combination of young people who were perinatally infected with HIV and those more recently infected, often through high‐risk behaviours [1](#jia225215-bib-0001){ref-type="ref"}. Many adolescents are not accessing HIV treatment or have challenges with adherence and retention in care, with subsequent poor health outcomes [2](#jia225215-bib-0002){ref-type="ref"}, [3](#jia225215-bib-0003){ref-type="ref"}, [4](#jia225215-bib-0004){ref-type="ref"}, [5](#jia225215-bib-0005){ref-type="ref"}.

Although UNAIDS Global AIDS Monitoring protocols recommend the collection and reporting of data in detailed age groups, only 84 of 178 (47%) countries reported age‐disaggregated paediatric data (separating 10‐ to 14‐ and 15‐ to 19‐year olds) in 2016 [6](#jia225215-bib-0006){ref-type="ref"}. The quality of the strategic information used to monitor the adolescent HIV epidemic and the impact of youth‐focused programmatic interventions could be enhanced by including routinely collected observational data from clinical and programme settings that are sufficiently detailed to be analysed by multiple categories (e.g. sex, age) and used to assess predictors of antiretroviral treatment (ART) outcomes. The objective of this analysis was to describe mortality and retention among a mixed population of adolescents living with HIV acquired perinatally as well as later in adolescence in routine care settings in low‐ and middle‐income countries in the International epidemiology Databases to Evaluate AIDS (IeDEA) cohort consortium.

2. Methods {#jia225215-sec-0006}
==========

2.1. Study population {#jia225215-sec-0007}
---------------------

IeDEA is a collaboration of clinical centres and research partners across seven global regions which was established in 2006 and is supported through the US National Institutes of Health (<https://www.iedea.org/>). For this analysis, data from 270 sites were included from six IeDEA regions (Asia‐Pacific, Central, East, West, and Southern Africa, the Caribbean and Central and South America (CCASAnet)), with data from Southern Africa separated into South Africa and the rest of Southern Africa due to variations in national paediatric HIV treatment guidelines (e.g. regarding use of protease inhibitors (PIs)) that resulted in differing treatment histories from other countries in that region. The analysis included all patients enrolled in HIV care at participating IeDEA sites from January 2003, and who had at least six months of potential follow‐up during adolescence (i.e. 10 to 19 years of age). Patients could have initiated antiretrovirals or remained antiretroviral‐naïve. The analysis database included data up to June 2016.

2.2. Ethics review {#jia225215-sec-0008}
------------------

Each region secured local regulatory approvals for participation in this analysis, including reviews by local research and ethics regulatory bodies and, where required, national‐level approvals. Consent and assent requirements and procedures were regulated by the local regulatory bodies, and adherence to those standards was the responsibility of each site while being monitored and managed by regional coordinating centres. (<https://www.iedea.org/regions/>) [7](#jia225215-bib-0007){ref-type="ref"}, [8](#jia225215-bib-0008){ref-type="ref"}, [9](#jia225215-bib-0009){ref-type="ref"}.

2.3. Definitions and measurements {#jia225215-sec-0009}
---------------------------------

Adolescents were defined as those 10 up to 19 years of age and the analysis focused on this period of life. The beginning of follow‐up, referred to as the "baseline" time point, was the date of the 10th birthday for those who entered care before age 10, and the date of the first clinic visit for those who entered care at or after age 10. Follow‐up time ended and data were censored at whichever of the following came first: (1) death, (2) transfer out, (3) loss to follow‐up (LTFU), (4) turning 19 years of age, or (5) the closing date of the individual regional cohort database. The main outcomes of interest were death, LTFU and transfer that occurred in the year following the last clinic visit during the period of adolescence. Specifically, adolescents without evidence of contact with the clinic for more than 12 months were classified as LTFU with their follow‐up period ending 12 months after their last clinic contact. In addition, if a patient previously considered LTFU was subsequently known to have died or have been transferred (e.g. through updated reporting by their clinic), their outcomes were revised up to 24 months after their last clinic contact (and not beyond turning age 19 or database closure).

HIV disease stage was categorized as asymptomatic (CDC N or WHO 1), mild (CDC A or WHO 2), moderate (CDC B or WHO 3) and severe (CDC C or WHO 4). Weight and height measurements were converted to age‐ and sex‐adjusted z‐scores. For weight‐for‐age z‐scores, US National Center for Health Statistics and WHO International Growth Reference standards were used to allow for scoring children \>10 years of age [10](#jia225215-bib-0010){ref-type="ref"}, [11](#jia225215-bib-0011){ref-type="ref"}. For height‐for‐age z‐score we used the WHO 2006/2007 Child Growth Standards [12](#jia225215-bib-0012){ref-type="ref"}, [13](#jia225215-bib-0013){ref-type="ref"}. Severe immunodeficiency was defined according to 2006 WHO global guidelines (e.g. \<15% or \<200 cells/mm^3^ for children ≥5 years old) [14](#jia225215-bib-0014){ref-type="ref"}.

For laboratory and clinical measurements, we used the closest values reported during a window of plus or minus three months from the baseline visit (i.e. at age 10 or the date of the first visit if entering care after age 10), with the pre‐baseline measurement used in the case of multiple values. At antiretroviral initiation, we used a testing window of three months before and one week after start (e.g. for CD4, viral load).

2.4. Statistical analysis {#jia225215-sec-0010}
-------------------------

The analysis was restricted to assess outcomes during the period of adolescence. Adolescents entering care before age 15 years were compared to those with a first visit at or after age 15. Entry into care before age 15 was considered a proxy for those likely to have been infected perinatally or very early in life compared to those infected in older adolescence, predominantly assumed to be through risk behaviours and called the "late‐infected" [15](#jia225215-bib-0015){ref-type="ref"}, [16](#jia225215-bib-0016){ref-type="ref"}, [17](#jia225215-bib-0017){ref-type="ref"}. The term "late‐infected" was chosen to characterize the timing of HIV infection relative to the stage of adolescence (i.e. between 15 and 19 years of age). The selection of the age threshold is consistent with UNAIDS Global AIDS Monitoring methods where those 10 to 14 years of age are considered to be in early adolescence and those 15 to 19 years in late adolescence. In addition, infections acquired through risk behaviours are not modelled in the UNAIDS Spectrum model to occur among those entering HIV care before the age of 15 years [6](#jia225215-bib-0006){ref-type="ref"}. We conducted a sensitivity analysis to examine the impact of differentiating patients by age \<10 versus ≥10 years at entry into care as a comparison [18](#jia225215-bib-0018){ref-type="ref"}.

To compare proportions, we used chi‐square tests, and we compared medians with the Mann--Whitney test. We used a cumulative incidence function to estimate the probabilities of death and LTFU during adolescence. In a subset of adolescents who had received ≥3 antiretrovirals as their initial treatment regimen, we conducted separate competing risks regression analyses based on Fine and Gray\'s proportional sub‐hazards model [19](#jia225215-bib-0019){ref-type="ref"} to identify correlates of death (LTFU as a competing event) and correlates of LTFU (death as a competing event) from the start of triple‐drug ART. The following variables were included in the univariate analysis: age and calendar year at first triple‐drug ART, sex, facility level and facility setting (as defined by the site). CD4 count and weight‐for‐age z‐scores were included as time‐updated variables, and their values were carried forward if no subsequent measurements were recorded. In regression analyses, missing data were modelled as a separate category within each variable. We did not use multiple imputation to model missing data due to the relatively small numbers of covariates available, and the resulting lack of precision in imputation. To assess the robustness of our analyses to missing data, we undertook a sensitivity analysis based on subsets of patients with complete data. Variables were included in the multivariate model if they had a *p* \< 0.2 in univariate analysis. We selected the final model using a backward elimination procedure and retained all variables in the model that had a *p* \< 0.05. The adjusted subdistribution hazard ratios (asHR) were reported with their 95% confidence intervals (95% CI).

Management of the multiregional aggregated data and statistical analyses were performed at the Kirby Institute, UNSW Australia, using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and Stata (StataCorp, STATA 14.0 for Windows, College Station, TX, USA).

3. Results {#jia225215-sec-0011}
==========

A total of 61,242 adolescents (61% female) were included from 270 sites in 34 countries (Figure [1](#jia225215-fig-0001){ref-type="fig"}): Asia‐Pacific (n = 2508, 4.1%; 16 sites), Central Africa (n = 2143, 3.5%; 15 sites), CCASAnet (n = 1728, 2.8%; 12 sites), East Africa (n = 10,767, 18%; 47 sites), South Africa (n = 15,494, 25%; 12 sites), Southern Africa (n = 25,102, 41%; 148 sites) and West Africa (n = 3500, 5.7%; 20 sites). Overall, 69% (n = 42,138) entered care before 15 years of age (perinatally infected) at a median age at first visit of 9.8 (interquartile range (IQR) 6.8 to 12.0) years (Table [1](#jia225215-tbl-0001){ref-type="table"}) and median duration of follow‐up during adolescence of 2.9 (IQR 1.4 to 5.0) years. Those entering care at or after age 15 (late‐infected) represented 31% (n = 19,104) of the adolescents, and had a median age at first visit of 17.5 (IQR 16.4 to 18.3) years and median duration of follow‐up during adolescence of 1.0 (IQR 0.9 to 1.6) year. Approximately one‐third of adolescents in CCASAnet (33%), and East (34%), South (37%), and Southern Africa (32%) were late‐infected, compared to 1.9% in the Asia‐Pacific, 13% in Central Africa and 19% in West Africa.

![Flow diagram for analysis cohort by age at entry into HIV care (N = 61,242). CCASA, Caribbean, Central America, South America; LTFU, lost to follow‐up.](JIA2-21-e25215-g001){#jia225215-fig-0001}

###### 

Characteristics at analysis baseline[a](#jia225215-note-0004){ref-type="fn"} for 61,242 patients who had a care visit at 10 to 19 years of age at an IeDEA site between 2003 and 2016

  Characteristics[b](#jia225215-note-0004){ref-type="fn"}                                                At age 10 or first visit if first visit \< age 15 N = 42,138 (68.8%)   At first visit if first visit ≥ age 15 N = 19,104 (31.2%)   *p*‐value
  ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------- ----------------------------------------------------------- -----------
  Sex                                                                                                                                                                                                                                       
  Male                                                                                                   19,816 (47.0)                                                          3638 (19.0)                                                 \<0.001
  Female                                                                                                 22,137 (52.5)                                                          15,420 (80.7)                                               
  Unknown                                                                                                185 (0.4)                                                              46 (0.3)                                                    
  Age at first clinic visit (years)                                                                                                                                                                                                         
  Median (IQR)                                                                                           9.8 (6.8, 12.0)                                                        17.5 (16.4, 18.3)                                           N/A
  Mean (SD)                                                                                              9.3 (3.48)                                                             17.3 (1.14)                                                 
  CD4 count (cells/mm^3^)                                                                                                                                                                                                                   
  \<200                                                                                                  6447 (15.3)                                                            3764 (19.7)                                                 \<0.001
  200 to 349                                                                                             4087 (9.7)                                                             3360 (17.6)                                                 
  350 to 499                                                                                             3668 (8.7)                                                             2508 (13.1)                                                 
  ≥500                                                                                                   11,176 (26.5)                                                          3617 (18.9)                                                 
  Unknown                                                                                                16,760 (39.8)                                                          5855 (30.7)                                                 
  Median (IQR)                                                                                           435 (196, 745)                                                         329 (178, 521)                                              \<0.001
  Mean (SD)                                                                                              513 (405.1)                                                            377 (274.3)                                                 \<0.001
  HIV viral load, copies/mL                                                                                                                                                                                                                 
  \<50                                                                                                   3026 (7.2)                                                             227 (1.2)                                                   \<0.001
  50 to 399                                                                                              1535 (3.6)                                                             132 (0.7)                                                   
  400 to 999                                                                                             472 (1.1)                                                              42 (0.2)                                                    
  1000 to 9999                                                                                           837 (2.0)                                                              157 (0.8)                                                   
  ≥10,000                                                                                                2199 (5.2)                                                             483 (2.5)                                                   
  Unknown                                                                                                34,069 (80.9)                                                          18,063 (94.6)                                               
  Median log~10~ (IQR) HIV‐RNA                                                                           2.4 (1.6, 4.2)                                                         3.9 (1.9, 4.9)                                              \<0.001
  Mean (SD)                                                                                              2.8 (1.60)                                                             3.6 (1.58)                                                  \<0.001
  WHO/CDC clinical stage                                                                                                                                                                                                                    
  WHO stage 1/CDC stage N                                                                                1759 (4.2)                                                             1808 (9.5)                                                  \<0.001
  WHO stage 2/CDC stage A                                                                                2613 (6.2)                                                             885 (4.6)                                                   
  WHO stage 3/CDC stage B                                                                                2638 (6.3)                                                             798 (4.2)                                                   
  WHO stage 4/CDC stage C                                                                                1872 (4.4)                                                             267 (1.4)                                                   
  Not documented                                                                                         33,256 (78.9)                                                          15,346 (80.3)                                               
  Weight‐for‐age z‐score                                                                                                                                                                                                                    
  \<−3                                                                                                   7179 (17.0)                                                            2079 (10.9)                                                 \<0.001
  −3 ≤  to \<−2                                                                                          6644 (15.8)                                                            1401 (7.3)                                                  
  −2 ≤  to \<−1                                                                                          9051 (21.5)                                                            2353 (12.3)                                                 
  ≥−1                                                                                                    7664 (18.2)                                                            6690 (35.0)                                                 
  Unknown                                                                                                11,600 (27.5)                                                          6581 (34.5)                                                 
  Median (IQR)                                                                                           −1.9 (−2.9, −1.0)                                                      −0.9 (−2.2, −0.1)                                           \<0.001
  Mean (SD)                                                                                              −2.1 (1.63)                                                            −1.3 (1.99)                                                 \<0.001
  Height‐for‐age z‐score                                                                                                                                                                                                                    
  \<−3                                                                                                   5254 (12.5)                                                            851 (4.5)                                                   \<0.001
  −3 ≤  to \<−2                                                                                          6896 (16.4)                                                            1348 (7.1)                                                  
  −2 ≤  to \<−1                                                                                          7642 (18.1)                                                            3138 (16.4)                                                 
  ≥−1                                                                                                    6422 (15.2)                                                            5136 (26.9)                                                 
  Unknown                                                                                                15,924 (37.8)                                                          8631 (45.2)                                                 
  Median (IQR)                                                                                           −1.9 (−2.8, −1.0)                                                      −1.0 (−1.9, −0.3)                                           \<0.001
  Mean (SD)                                                                                              −1.9 (1.42)                                                            −1.1 (1.35)                                                 \<0.001
  Timing of antiretrovirals[c](#jia225215-note-0004){ref-type="fn"}                                                                                                                                                                         
  Started before baseline                                                                                17,420 (41.3)                                                          164 (0.9)                                                   \<0.001
  Started at baseline                                                                                    4982 (11.8)                                                            3232 (16.9)                                                 
  Type of regimen[c](#jia225215-note-0004){ref-type="fn"} ^,^ [d](#jia225215-note-0004){ref-type="fn"}                                                                                                                                      
  3‐ART‐NNRTI                                                                                            18,389 (82.1)                                                          2822 (83.1)                                                 \<0.001
  3‐ART‐PI                                                                                               1489 (6.7)                                                             147 (4.3)                                                   
  3‐ART‐NNRTI/PI based                                                                                   55 (0.3)                                                               2 (0.1)                                                     
  3‐ART‐other                                                                                            52 (0.2)                                                               11 (0.3)                                                    
  Mono/dual                                                                                              2417 (10.8)                                                            414 (12.2)                                                  
  Most frequent antiretroviral regimen[c](#jia225215-note-0004){ref-type="fn"}                                                                                                                                                              
  3TC/d4T/EFV                                                                                            4105 (18.3)                                                            191 (5.6)                                                   \<0.001
  3TC/d4T/NVP                                                                                            3759 (16.8)                                                            265 (7.8)                                                   
  3TC/AZT/NVP                                                                                            3362 (15.0)                                                            184 (5.4)                                                   
  3TC/AZT/EFV                                                                                            2418 (10.8)                                                            156 (4.6)                                                   
  ABC/3TC/EFV                                                                                            2264 (10.1)                                                            53 (1.6)                                                    
  ABC/3TC/NVP                                                                                            1344 (6.0)                                                             16 (0.5)                                                    
  FTC/EFV/TDF                                                                                            313 (1.4)                                                              1057 (31.1)                                                 
  3TC/EFV/TDF                                                                                            314 (1.4)                                                              653 (19.2)                                                  
  3TC/NVP/TDF                                                                                            47 (0.2)                                                               153 (4.6)                                                   
  Others[e](#jia225215-note-0004){ref-type="fn"}                                                         4476 (20.0)                                                            668 (19.7)                                                  
  Duration on antiretrovirals, years[f](#jia225215-note-0004){ref-type="fn"}                                                                                                                                                                
  \<1                                                                                                    3765 (21.6)                                                            91 (55.5)                                                   \<0.001
  1 to 2                                                                                                 5764 (33.1)                                                            27 (16.5)                                                   
  ≥3                                                                                                     7891 (45.3)                                                            46 (28.1)                                                   
  Median (IQR)                                                                                           2.7 (1.2, 4.6)                                                         0.6 (0.1, 3.9)                                              \<0.001
  Mean (SD)                                                                                              3.1 (2.29)                                                             2.1 (2.55)                                                  \<0.001

Data are presented as n (%) unless otherwise noted. We used the 1977 WHO growth curve for weight‐for‐age z‐score (more recent weight curves are limited to children age ≤10 years) and the 2006/2007 WHO growth curve for height‐for‐age z‐score. 3‐ART, antiretroviral therapy regimen of three or more antiretrovirals; IQR, interquartile range; NNRTI, non‐nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; mono/dual, single or two drugs; SD, standard deviation.

^a^Baseline was the date of the 10th birthday for those who entered care before age 10, and the date of the first clinic visit for those who entered care at or after age 10. ^b^IeDEA regions utilize a common data exchange standard for harmonizing data for use in multiregional analyses that includes formats and categorizations for specific data variables that are available at iedeades.org. ^c^This only includes those who were on antiretrovirals at baseline. Those who started before baseline and stopped before baseline and those who started antiretrovirals after baseline were not included. ^d^3‐ART represents triple‐drug regimens. The drug class following that term denotes where one of the drugs included either an NNRTI, PI, or both classes; "other" represents triple‐drug regimens without an NNRTI or PI. Non‐3‐ART represents regimens with fewer than three individual antiretroviral drugs. ^e^Includes other triple‐drug and mono/dual antiretroviral combinations. ^f^Duration has been calculated for adolescents who started antiretrovirals before baseline and were still on them at baseline.
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At baseline (age 10 years or first clinic visit if entering care later), antiretrovirals had already been started by 41% of perinatally infected adolescents and 0.9% of late‐infected adolescents. The median CD4 count was 435 (IQR 196 to 745) cells/mm^3^ for those perinatally infected and 329 (IQR 178 to 521) cells/mm^3^ for the late‐infected; higher proportions of perinatally infected were severely underweight (17% vs. 11%, *p *\<* *0.001) and severely stunted (13% vs. 4.5%, *p *\<* *0.001) with z‐scores \<−3 compared to late‐infected adolescents. At baseline, HIV viral load was infrequently available in both groups (19% vs. 5.4%). Of those with a viral load measurement at baseline, 38% of the perinatally infected and 22% of the late‐infected were undetectable.

3.1. Antiretroviral use {#jia225215-sec-0012}
-----------------------

A total of 44,922 adolescents ever initiated any combination of antiretroviral drugs by the end of the follow‐up period (84% perinatally vs. 51% late‐infected; Table [S1](#jia225215-sup-0001){ref-type="supplementary-material"}). Median CD4 percent at antiretroviral initiation was 12% (IQR 6% to 18%) among the perinatally infected and 14% (IQR 7% to 23%) among late‐infected adolescents (*p *\<* *0.001). Perinatally infected adolescents had a greater degree of severe immunodeficiency (59% vs. 51%; *p *\<* *0.001) and were more likely to be severely underweight (22% vs. 13%; *p *\<* *0.001) and stunted (16% vs. 4.6%; *p *\<* *0.001) at antiretroviral start. The median lifetime duration of antiretroviral use was 4.8 (IQR 2.4 to 7.3) years among those entering care before age 15 years, and 1.1 (IQR 0.8 to 1.8) years for those entering at ≥15 years.

3.2. Patient outcomes {#jia225215-sec-0013}
---------------------

During the adolescent follow‐up period, 3.9% died, 30% were LTFU and 8.1% were transferred. Separated by age at cohort entry, among those entering care before age 15 years, 4.0% died, 27% were LTFU, and 9.7% transferred (Table [S2](#jia225215-sup-0001){ref-type="supplementary-material"}). For those entering care at or after age 15 years, 3.8% died, 38% were LTFU and 4.6% were transferred. These data include 62 adolescents living with HIV (ALHIV) who were recategorized from LTFU to dead and 98 recategorized to transferred between 12 and 24 months after most recent clinic contact (and before age 19 or database closure). Among perinatally infected adolescents, the four‐year cumulative incidence of death was 3.9% and of LTFU was 26%, while for late‐infected adolescents it was 5.4% for death and 69% for LTFU; both outcomes were significantly higher in late‐infected adolescents (*p *\<* *0.001) (Figure [2](#jia225215-fig-0002){ref-type="fig"}).

![Estimated cumulative incidences of death and loss to follow‐up using competing risk methods, among adolescents (10 to 19 years) enrolled at 270 IeDEA clinical sites from 2003 to 2016, by age at first clinic visit (n = 61,242).](JIA2-21-e25215-g002){#jia225215-fig-0002}

In the sensitivity analysis where age at entry into care was redefined as \<10 years versus ≥10 years, the median CD4 at baseline for the group entering care at \<10 years of age (n = 22,168) was 673 (IQR 429 to 949) cells/mm^3^. The proportion of adolescents entering care before age 10 years who died was 1.9%, compared to 4.0% using the age 15 threshold, and the proportion who were LTFU was 18% compared to 27% (Table [S3](#jia225215-sup-0001){ref-type="supplementary-material"}). In addition, of the 19,970 adolescents entering care between age 10 and 14 years, 1247 (6.2%) died and 7469 (37%) were LTFU by the age of 19 years.

The multivariate regression model restricted to those who received triple‐drug ART as their initial antiretroviral regimen showed that there was an increase in the hazard rate of death for those starting treatment at older ages compared to those \<5 years of age (5 to 9 years adjusted subdistribution hazard ratios asHR 2.59, 95% CI 1.74 to 3.85; 10 to 14 years asHR 6.93, 95% CI 4.69 to 10.22; ≥15 years asHR 8.72, 95% CI 5.85 to 13.02) (Table [2](#jia225215-tbl-0002){ref-type="table"}). The hazard was higher for females (asHR 1.19, 95% CI 1.07 to 1.33), and those receiving care in mostly urban (asHR 1.40, 95% CI 1.13 to 1.75) and mostly rural settings (asHR 1.39, 95% CI 1.03 to 1.87) compared to urban settings. The hazard of death was lower for those with higher CD4 count, better weight‐for‐age z‐scores, receiving care at a district hospital and in rural settings compared to health centres and in urban settings, with a later year of starting ART, and for cohorts from the Asia‐Pacific, Central Africa, East Africa, and South Africa compared to Southern Africa. Hazard rates of death were lowest overall among adolescents with a current CD4 ≥500 cells/mm^3^ compared to \<200 cells/mm^3^ (asHR 0.12, 95% CI 0.10 to 0.15), a weight‐for‐age z‐score ≥−2 compared to \<−3 (asHR 0.22, 95% CI 0.19 to 0.25), initiating ART between 2011 and 2016 compared to 2003 and 2006 (asHR 0.36, 95% CI 0.31 to 0.43), or receiving care in South Africa compared to Southern Africa (asHR 0.45, 95% CI 0.36 to 0.57).

###### 

Factors associated with death during the adolescent period (10 to 19 years of age) in 39,262 patients who received ≥3 antiretroviral drugs as initial HIV treatment regimens

  Characteristics                                                           Total (N = 39,262)   Deaths (N = 1518)   Univariate            Multivariate                        
  ------------------------------------------------------------------------- -------------------- ------------------- --------------------- -------------- -------------------- ---------
  Sex                                                                                                                                                                          
  Male                                                                      16,475               681                 1.00                                 1.00                 
  Female                                                                    22,640               832                 0.99 (0.90, 1.10)     0.899          1.19 (1.07, 1.33)    0.001
  Age at ≥3‐drug ART (years)                                                                                                                                                   
  \<5                                                                       3006                 26                  1.00                                 1.00                 
  5 to 9                                                                    11,923               248                 3.05 (2.05, 4.53)     \<0.001        2.59 (1.74, 3.85)    \<0.001
  10 to 14                                                                  14,522               844                 11.28 (7.73, 16.45)   \<0.001        6.93 (4.69, 10.22)   \<0.001
  ≥15                                                                       9811                 400                 11.26 (7.67, 16.52)   \<0.001        8.72 (5.85, 13.02)   \<0.001
  Current CD4 count (cells/mm^3^)[a](#jia225215-note-0006){ref-type="fn"}                                                                                                      
  \<200                                                                     ‐                    913                 1.00                                                      
  200 to 349                                                                ‐                    162                 0.20 (0.17, 0.23)     \<0.001        0.27 (0.23, 0.32)    \<0.001
  350 to 499                                                                ‐                    121                 0.15 (0.13, 0.18)     \<0.001        0.23 (0.19, 0.28)    \<0.001
  ≥500                                                                      ‐                    170                 0.06 (0.05, 0.07)     \<0.001        0.12 (0.10, 0.15)    \<0.001
  Current weight‐for‐age z score[a](#jia225215-note-0006){ref-type="fn"}                                                                                                       
  \<−3                                                                      ‐                    834                 1.00                                 1.00                 
  −3 ≤  to \<−2                                                             ‐                    199                 0.22 (0.19, 0.26)     \<0.001        0.34 (0.29, 0.40)    \<0.001
  ≥−2                                                                       ‐                    325                 0.12 (0.11, 0.14)     \<0.001        0.22 (0.19, 0.25)    \<0.001
  Facility level                                                                                                                                                               
  Health centre                                                             16,068               532                 1.00                                                      
  District hospital                                                         6708                 232                 1.11 (0.95, 1.30)     0.174          0.76 (0.64, 0.91)    0.003
  Regional, provincial, or university hospital                              13,214               635                 1.31 (1.17,1.47)      \<0.001        1.02 (0.86, 1.22)    0.800
  Facility setting                                                                                                                                                             
  Urban                                                                     16,141               750                 1.00                                 1.00                 
  Mostly urban                                                              4857                 241                 1.10 (0.95, 1.30)     0.184          1.40 (1.13, 1.75)    0.002
  Mostly rural                                                              2758                 114                 1.04 (0.85, 1.26)     0.723          1.39 (1.03, 1.87)    0.032
  Rural                                                                     12,184               291                 0.57 (0.49, 0.65)     \<0.001        0.76 (0.63, 0.91)    0.003
  Region                                                                                                                                                                       
  Southern Africa                                                           11,640               528                 1.00                                 1.00                 
  Asia‐Pacific                                                              2295                 85                  0.62 (0.49, 0.78)     0.001          0.54 (0.39, 0.75)    0.001
  Caribbean, Central and South America                                      1473                 114                 1.40 (1.15, 1.72)     0.001          0.96 (0.72, 1.26)    0.748
  Central Africa                                                            1660                 54                  0.59 (0.45, 0.78)     \<0.001        0.68 (0.48, 0.95)    0.026
  East Africa                                                               7476                 303                 0.90 (0.78, 1.04)     0.160          0.49 (0.37, 0.65)    \<0.001
  South Africa                                                              11,574               202                 0.35 (0.29, 0.41)     \<0.001        0.45 (0.36, 0.57)    \<0.001
  West Africa                                                               3144                 232                 1.37 (1.18, 1.60)     \<0.001        1.02 (0.80, 1.30)    0.859
  Year of first ≥3‐drug ART                                                                                                                                                    
  2003 to 2006                                                              8560                 554                 1.00                                 1.00                 
  2007 to 2010                                                              14,553               659                 0.83 (0.74, 0.92)     0.001          0.69 (0.61, 0.78)    \<0.001
  2011 to 2016                                                              16,149               305                 0.49 (0.43, 0.57)     \<0.001        0.36 (0.31, 0.43)    \<0.001

Loss to follow‐up (n = 9131) was a competing event for death in this analysis and death was a competing event for loss to follow‐up. Total numbers include missing values (not shown in the table). Missing values were included as a separate category in all analyses. 95% CI, 95% confidence interval; asHR, adjusted subdistribution hazard ratio.

CD4 count and weight‐for‐age z score were considered time‐dependent variables. Total number was not given as adolescents moved between categories.
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Increased hazard rates of LTFU among adolescents who received triple‐drug ART as their initial antiretroviral regimen were associated with female sex (asHR 1.12, 95% CI 1.07 to 1.17), older age at ART start compared to \<5 years (5 to 9 years asHR 2.59, 95% CI 2.32 to 2.88; 10 to 14 years asHR 6.11, 95% CI 5.49 to 6.81; ≥15 years asHR 11.11, 95% CI 9.86 to 12.53), receiving care at a district hospital compared to a health centre (asHR 1.27, 95% CI 1.18, 1.37), receiving care in rural compared to urban settings (asHR 1.21, 95% CI 1.13, 1.29), receiving care in East Africa (asHR 1.14, 95% CI 1.01 to 1.28), South Africa (asHR 1.75, 95% CI 1.63 to 1.88), or CCASAnet (asHR 2.99, 95% CI 2.65 to 3.36) compared to Southern Africa, and starting triple‐drug ART after 2006 (highest asHR for 2011 to 2016 1.84, 95% CI 1.71 to 1.99) (Table [3](#jia225215-tbl-0003){ref-type="table"}). In contrast, lower hazard rates of LTFU were associated with CD4 count ≥350 cells/mm^3^ (lowest asHR for ≥500 0.65, 95% CI 0.61 to 0.69), receiving care in regional, provincial, or university hospitals compared to health centres (asHR 0.63, 95% CI 0.58 to 0.68), receiving care in mostly urban and mostly rural compared to urban settings (lowest asHR for mostly urban 0.71, 95% CI 0.62 to 0.81), and receiving care in the Asia‐Pacific compared to Southern Africa (asHR 0.19, 95% CI 0.14 to 0.25).

###### 

Factors associated with LTFU during the adolescent period (10 to 19 years of age) in 39,262 patients who received ≥3 antiretroviral drugs as initial HIV treatment regimens

  Characteristics                                                           Total (N = 39,262)   LTFU (N = 9131)   Univariate             Multivariate                         
  ------------------------------------------------------------------------- -------------------- ----------------- ---------------------- -------------- --------------------- ---------
  Sex                                                                                                                                                                          
  Male                                                                      16,475               3753              1.00                                  1.00                  \<0.001
  Female                                                                    22,640               5374              1.33 (1.27, 1.38)      \<0.001        1.12 (1.07, 1.17)     
  Age at ≥3‐drug ART (years)                                                                                                                                                   
  \<5                                                                       3006                 304               1.00                                  1.00                  
  5 to 9                                                                    11,923               2198              3.17 (2.84, 3.54)      \<0.001        2.59 (2.32, 2.88)     \<0.001
  10 to 14                                                                  14,522               4142              9.90 (8.91, 11.00)     \<0.001        6.11 (5.49, 6.81)     \<0.001
  ≥15                                                                       9811                 2487              24.54 (21.94, 27.46)   \<0.001        11.11 (9.86, 12.53)   \<0.001
  Current CD4 count (cells/mm^3^)[a](#jia225215-note-0008){ref-type="fn"}                                                                                                      
  \<200                                                                     ‐                    1824              1.00                                  1.00                  
  200 to 349                                                                ‐                    1489              0.92 (0.86, 0.99)      0.017          1.01 (0.94, 1.08)     0.777
  350 to 499                                                                ‐                    1143              0.57 (0.53, 0.61)      \<0.001        0.72 (0.67, 0.78)     \<0.001
  ≥500                                                                      ‐                    3076              0.35 (0.33, 0.37)      \<0.001        0.65 (0.61, 0.69)     \<0.001
  Current weight‐for‐age z score[a](#jia225215-note-0008){ref-type="fn"}                                                                                                       
  \<−3                                                                      ‐                    1448              1.00                                                        
  −3 ≤  to \<−2                                                             ‐                    1046              0.64 (0.59, 0.69)      \<0.001        0.93 (0.86, 1.01)     0.079
  ≥−2                                                                       ‐                    3252              0.65 (0.61, 0.69)      \<0.001        0.94 (0.88, 1.01)     0.087
  Facility level                                                                                                                                                               
  Health centre                                                             16,068               4747              1.00                                  1.00                  
  District hospital                                                         6708                 1527              0.84 (0.79, 0.89)      \<0.001        1.27 (1.18, 1.37)     \<0.001
  Regional, provincial, or university hospital                              13,214               2091              0.37 (0.35, 0.39)      \<0.001        0.63 (0.58, 0.68)     \<0.001
  Facility location                                                                                                                                                            
  Urban                                                                     16,141               3185              1.00                                                        
  Mostly urban                                                              4857                 545               0.58 (0.53, 0.64)      \<0.001        0.71 (0.62, 0.81)     \<0.001
  Mostly rural                                                              2758                 401               0.99 (0.90, 1.10)      0.914          0.75 (0.64, 0.87)     \<0.001
  Rural                                                                     12,184               4223              2.70 (2.58, 2.82)      \<0.001        1.21 (1.13, 1.29)     \<0.001
  Region                                                                                                                                                                       
  Southern Africa                                                           11,640               2776              1.00                                  1.00                  
  Asia‐Pacific                                                              2295                 49                0.04 (0.03, 0.06)      \<0.001        0.19 (0.14, 0.25)     \<0.001
  Caribbean, Central and South America                                      1473                 649               1.21 (1.12, 1.31)      0.822          2.99 (2.65, 3.36)     \<0.001
  Central Africa                                                            1660                 266               0.42 (0.37, 0.47)      \<0.001        0.93 (0.80, 1.08)     0.347
  East Africa                                                               7476                 1152              0.61 (0.57, 0.66)      \<0.001        1.14 (1.01, 1.28)     0.028
  South Africa                                                              11,574               3850              1.22 (1.16, 1.28)      \<0.001        1.75 (1.63, 1.88)     0.001
  West Africa                                                               3144                 389               0.31 (0.28, 0.35)      \<0.001        0.93 (0.81, 1.06)     0.288
  Year of first ≥3‐drug ART                                                                                                                                                    
  2003 to 2006                                                              8560                 1940              1.00                                  1.00                  
  2007 to 2010                                                              14,553               3689              2.11 (1.99, 2.24)      \<0.001        1.24 (1.16, 1.32)     \<0.001
  2011 to 2016                                                              16,149               3502              5.36 (5.03, 5.72)      \<0.001        1.84 (1.71, 1.99)     \<0.001

Death (n = 1518) was a competing event for LTFU in this analysis and loss to follow‐up was a competing event for death. Total numbers include missing values (not shown in the table). Missing values were included as a separate category in all analyses. 95% CI, 95% confidence interval; asHR, adjusted subdistribution hazard ratio; LTFU, loss to follow‐up.

CD4 count and weight‐for‐age z score were considered time‐dependent variables. Total number was not given as adolescents moved between categories.
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The sensitivity analyses excluding missing data gave qualitatively very similar results for most covariates (data not shown). The only exceptions were in mortality analyses, where survival was no longer improved in Central Africa (asHR in sensitivity analysis of 1.10 95% CI 0.71 to 1.70, compared with asHR in main analysis of 0.68 95% 0.48 to 0.95), or in rural settings (asHR in sensitivity analysis of 1.02 95% CI 0.82 to 1.27, compared with asHR in main analysis of 0.76 95% 0.63 to 0.91). Importantly, results for individual‐level covariates such as age, sex and CD4 count, were qualitatively the same.

4. Discussion {#jia225215-sec-0014}
=============

This is the first IeDEA multiregional cohort analysis to reflect the complexity of the mixed adolescent HIV epidemic including both individuals with perinatally acquired HIV and those infected later. Among the 61,242 adolescents in our analysis, 69% entered care before the age of 15 (our proxy for perinatally acquired infection), but not until a median age of 9.8 years. While the cumulative incidence of both mortality and LTFU were higher among those entering care at ≥15 years (our proxy for infection acquired later during adolescence), the qualitative differences in mortality over this period were small. However, the sensitivity analysis demonstrated a higher burden of mortality among those perinatally infected adolescents who did not enter care until 10 to 14 years of age. Our overall four‐year cumulative incidence of death of 4.2% compares to the post‐ART mortality incidence rate of 0.97 per 100 person‐years among children five to nine years of age in IeDEA [20](#jia225215-bib-0020){ref-type="ref"}, and rates among youth starting ART during the ages of 15 to 24 years from 0.8 per 100 in Nigeria up to 13.5 per 100 in Tanzania in a seven‐African country analysis [2](#jia225215-bib-0002){ref-type="ref"}.

From our regression model, most factors found to be protective against death among those who started treatment with triple‐drug ART were consistent with other studies (e.g. better immune control, higher weight‐for‐age z‐score) [4](#jia225215-bib-0004){ref-type="ref"}, [21](#jia225215-bib-0021){ref-type="ref"}, [22](#jia225215-bib-0022){ref-type="ref"}. Any CD4 category ≥200 cells/mm^3^ or weight‐for‐age z‐score better than or equal to −3 was highly protective; as was starting triple‐drug ART after 2011, which may reflect scale‐up and quality improvement of paediatric HIV programmes and broadening treatment access in our settings [23](#jia225215-bib-0023){ref-type="ref"}, [24](#jia225215-bib-0024){ref-type="ref"}. Among those who had not received treatment, the median duration of follow‐up during adolescence was only one year and 52% were LTFU, making reliable ascertainment of mortality difficult in this sub‐group. The associations with regional cohort may reflect variations in national infrastructures for HIV and availability of other supportive healthcare services in the context of background country development [2](#jia225215-bib-0002){ref-type="ref"}, [25](#jia225215-bib-0025){ref-type="ref"}, [26](#jia225215-bib-0026){ref-type="ref"}, [27](#jia225215-bib-0027){ref-type="ref"}.

The overall high cumulative incidence of LTFU was concerning. Losses among those presenting to care during late adolescence rose sharply starting in the first year of follow‐up, whereas losses among the perinatally infected steadily increased over time. The four‐year cumulative incidence of LTFU during adolescence was 26% for the perinatally infected and almost three times that at 69% for the late‐infected. This compares to data from adolescents and young adults 15 to 24 years of age at treatment initiation in seven African countries, where LTFU ranged from 7.1% in Uganda to 30% in Tanzania [2](#jia225215-bib-0002){ref-type="ref"}. The rapid early losses are also consistent with levels of LTFU, approximately 30%, documented in prevention of mother‐to‐child HIV transmission Option B+ programmes [28](#jia225215-bib-0028){ref-type="ref"}, [29](#jia225215-bib-0029){ref-type="ref"}. While we did not have access to pregnancy data to confirm whether young women entered HIV care through antenatal care, being female was a risk factor for LTFU. While current universal treatment recommendations may reduce the early LTFU that was previously associated with delays related to CD4 testing [30](#jia225215-bib-0030){ref-type="ref"}, [31](#jia225215-bib-0031){ref-type="ref"}, [32](#jia225215-bib-0032){ref-type="ref"}, there are also studies among adolescents and adults reporting greater attrition among those started on ART at higher CD4 counts who have not experienced clinical disease progression [33](#jia225215-bib-0033){ref-type="ref"}, [34](#jia225215-bib-0034){ref-type="ref"}, [35](#jia225215-bib-0035){ref-type="ref"}.

The associations between LTFU and older age, as well as later year at cohort entry, may be related to having less time to return to care after an interruption (i.e. patient churn), survival bias among those who started treatment as younger children, or the poorer retention often seen among older adolescents and young adults [2](#jia225215-bib-0002){ref-type="ref"}, [36](#jia225215-bib-0036){ref-type="ref"}, [37](#jia225215-bib-0037){ref-type="ref"}, [38](#jia225215-bib-0038){ref-type="ref"}, [39](#jia225215-bib-0039){ref-type="ref"}. Receiving care in rural settings was associated with higher LTFU, but protective against death, which may suggest under ascertainment of mortality in rural areas where out migration in sub‐Saharan Africa has been common [40](#jia225215-bib-0040){ref-type="ref"}, [41](#jia225215-bib-0041){ref-type="ref"}. The reasons for the associations with regional cohort are unclear, and could be due to varying proportions of perinatally infected youth, local patient case mix, or other socio‐economic or demographic factors [18](#jia225215-bib-0018){ref-type="ref"}, [28](#jia225215-bib-0028){ref-type="ref"}, [42](#jia225215-bib-0042){ref-type="ref"}, [43](#jia225215-bib-0043){ref-type="ref"}. In addition, regional cohorts with sites within areas with a high density of ART programmes may see more "silent transfers," where patients move between clinics without formal referrals.

The median baseline CD4 count for the group entering care between 15 and 19 years was unexpectedly low at 329 cells/mm^3^, implying that there may have been perinatally infected adolescents mixed into this group who entered care at older ages with advanced HIV disease. This may reflect the health status of older slow progressors among perinatal adolescent survivors or the potential contribution of rapid disease progressors among those infected during adolescence. Age alone may be insufficient to avoid misclassification, and more complex algorithms to assess combinations of routinely available variables (e.g. weight, height and CD4 count) would help to disaggregate data [15](#jia225215-bib-0015){ref-type="ref"}.

Our analysis was limited by the use of routinely collected clinical data, which were incomplete. We included children with missing data in analyses using missing value categories in covariates, which has the advantage of maximising the sample size. Sensitivity analyses which excluded missing data gave very similar results, but did result in some changes in differences in survival between regions and facility setting. These site‐level covariates should be interpreted especially cautiously. Beyond variations in clinical resources and programme policies, some of the regions had more older female adolescents enrolled, which may have been associated with antenatal care programmes where early LTFU rates have been high [28](#jia225215-bib-0028){ref-type="ref"}. Our focus on those 10 to 19 years of age results in a survivor bias, as individuals who were perinatally infected would have had to survive childhood in order to be eligible for inclusion. In addition, our age proxy for perinatally acquired infection may have miscategorized those presenting very late to care as being infected during adolescence. Restricting inclusion in the analysis to those with at least six months of data may have resulted in underreporting of LTFU. While we allowed for randomly collected tracing data to reclassify outcomes, we did not systematically adjust for the risk of unascertained mortality among those LTFU.

5. Conclusions {#jia225215-sec-0015}
==============

In this global analysis of adolescent outcomes in IeDEA, 3.9% of ALHIV were reported to have died and 30% were LTFU, with both rates higher in those entering care after age 15. However, those entering care between 10 and 15 years were at higher risk of death than those in care before age 10, reflecting the severe immunodeficiency associated with delayed diagnoses. Greater prioritization of adolescents for clinical and social support is urgently needed to retain youth in HIV treatment programmes as they transition through adolescence into adult life.
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